HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex

Keita Yamana; Riku Kawasaki; Kousuke Kondo; Hidetoshi Hirano; Shogo Kawamura; Yu Sanada; Kaori Bando; Anri Tabata; Hideki Azuma; Takushi Takata; Yoshinori Sakurai; Hiroki Tanaka; Tomoki Kodama; Seiji Kawamoto; Takeshi Nagasaki; Atsushi Ikeda

doi:10.1039/D3NA00028A

HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex†

Keita Yamana,‡^a Riku Kawasaki,

‡*^a Kousuke Kondo,‡^a Hidetoshi Hirano,^a Shogo Kawamura,^a Yu Sanada,^b Kaori Bando,^c Anri Tabata,^c Hideki Azuma,^c Takushi Takata,^b Yoshinori Sakurai,^b Hiroki Tanaka,^b Tomoki Kodama,^d Seiji Kawamoto,^d Takeshi Nagasaki^c and Atsushi Ikeda

*^a

Author affiliations

* Corresponding authors

^a Program of Applied Chemistry, Graduate School of Advanced Science and Engineering, 1-4-1 Kagamiyama, Higashi-Hiroshima City, Japan
E-mail: riku0528@hiroshima-u.ac.jp, aikeda@hiroshima-u.ac.jp

^b Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2, Asahiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan

^c Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka Metropolitan University, 3-3-138 Sugimoto, Sumiyoshi-ku, Osaka City, Japan

^d Program of Biotechnology, Graduate School of Integrated Sciences for Life, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima, Japan

Abstract

The development of boron agents with integrated functionality, including biocompatibility, high boron content, and cancer cell targeting, is desired to exploit the therapeutic efficacy of boron neutron capture therapy (BNCT). Here, we report the therapeutic efficacy of BNCT using a HER-2-targeted antibody-conjugated boron nitride nanotube/β-1,3-glucan complex. The anticancer effect of BNCT using our system was 30-fold that of the clinically available boron agent L-BPA/fructose complex.

This article is part of the themed collections: World Cancer Day 2024: Showcasing cancer research across the RSC, Nanoparticle-based cancer therapies and Celebrating nanoscience in Japan and South Korea

Nanoscale Advances

HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex†

Abstract

Supplementary files

Article information

Download Citation

Permissions

HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex

Social activity

Search articles by author

Spotlight

Advertisements